147695-56-5

Basic information

• Product Name: 4-bromophenyl isoselenocyanate
• Synonyms: 4-bromophenyl isoselenocyanate
• CAS NO: 147695-56-5
• Molecular Weight: 260.979
• Mol File: 147695-56-5.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: 4-bromophenyl isoselenocyanate(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromophenyl isoselenocyanate(147695-56-5)
• EPA Substance Registry System: 4-bromophenyl isoselenocyanate(147695-56-5)

Safety Data

• Hazardous Substances Data: 147695-56-5(Hazardous Substances Data)

Upstream product

• 32315-10-9 bis(trichloromethyl) carbonate 
• 106-40-1 4-bromo-aniline 
• 64-18-6 formic acid 
• 2617-78-9 N-(4-bromophenyl)formamide 
• 33554-73-3 1-bromo-4-isocyanobenzene 

Downstream Products

• 685901-65-9 3-acetyl-N-(4-bromophenyl)-4-diethylaminoselenet-2(2H)-imine 
• 1453815-66-1 1-(4-bromophenyl)-5-[(3,5-dinitrobenzyl)selanyl]-1H-tetrazole 
• 1453815-67-2 N-(4-Bromphenyl)-N-(3,5-dinitrobenzyl)cyanamide 
• 1453815-68-3 (Z)-Se-(3,5-dinitrobenzyl)-N-cyano-N,N'-di(4-bromophenyl)isoselenourea 
• 60592-84-9 N-(4-bromophenyl)cyanamide 
• 66497-33-4 (4-bromo-phenyl)-selenourea 
• 32380-19-1 N-(4-bromophenyl)-5-(4-methylphenyl)-1,3,4-oxadiazol-2-amine 
• 1272399-07-1 3-amino-2-(4-bromophenylimino)-1,3-selenazolidin-4-one 

Relevant articles and documents

Discovery of New Selenoureido Analogues of 4-(4-Fluorophenylureido)benzenesulfonamide as Carbonic Anhydrase Inhibitors

A series of benzenesulfonamides bearing selenourea moieties was obtained considering the ureido-sulfonamide SLC-0111, in Phase I clinical trials as antitumor agent, as a lead molecule. All compounds showed interesting inhibition potencies against the physiologically relevant human (h) carbonic anhydrase (hCAs, EC 4.2.1.1) isoforms I, II, IV, and IX. The most flexible analogues in the series 14-19 showed low nanomolar inhibition constants against hCA I, II, and IX. We assessed selected compounds on the in vitro antioxidant properties and binding modes and evaluated ex vivo human prostate (PC3), breast (MDA-MB-231), and colon-rectal (HT-29) cancer cell lines both in normoxic and hypoxic conditions.

1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria

In this work, a new class of highly potent antituberculosis agents, 1-substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their oxa and selanyl analogs, is described. The minimal inhibitory concentration (MIC) values reached 1 μM (0.36-0.44 μg/mL) against Mycobacterium tuberculosis CNCTC My 331/88 and 0.25-1 μM against six multidrug-resistant clinically isolated strains of M. tuberculosis. The antimycobacterial effects of these compounds were highly specific because they were ineffective against all eight bacterial strains and eight fungal strains studied. Furthermore, these compounds exhibited low in vitro toxicity in four mammalian cell lines (IC50 > 30 μM). We also examined the structure-activity relationships of the compounds, particularly the effects on antimycobacterial activity of the number and position of the nitro groups, the linker between tetrazole and benzyl moieties, and the tetrazole itself. Relatively high variability of substituent R 1 on the tetrazole in the absence of negative effects on antimycobacterial activity allows further structural optimization with respect to toxicity and the ADME properties of the 1-substituted-5-[(3,5-dinitrobenzyl) sulfanyl]-1H-tetrazoles lead compounds.

Efficient synthesis of 4H-benzo[d][1,3]oxazin-4-ones from anthranilic acids and aryl isoselenocyanates

A synthesis in good to excellent yields of 23 4H-benzo[d][1,3]oxazin-4- ones, 18 of which are novel, from monosubstituted anthranilic acids and variously substituted phenyl isoselenocyanates without using any harsh reagents has been developed. The Se powder precipitated during the reaction could be efficiently recycled for the preparation of the aryl isoselenocyanates.